Pennsylvania Trust Co decreased its holdings in shares of Viewray Inc (NASDAQ:VRAY) by 6.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 117,641 shares of the company’s stock after selling 7,800 shares during the quarter. Pennsylvania Trust Co owned approximately 0.12% of Viewray worth $341,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in VRAY. Park West Asset Management LLC boosted its holdings in shares of Viewray by 87.3% during the 2nd quarter. Park West Asset Management LLC now owns 7,615,325 shares of the company’s stock worth $67,091,000 after buying an additional 3,549,255 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Viewray by 13.5% during the 2nd quarter. Perceptive Advisors LLC now owns 5,455,243 shares of the company’s stock worth $48,061,000 after buying an additional 649,593 shares during the period. BlackRock Inc. boosted its holdings in shares of Viewray by 1.5% during the 2nd quarter. BlackRock Inc. now owns 4,894,543 shares of the company’s stock worth $43,121,000 after buying an additional 72,529 shares during the period. Vanguard Group Inc. boosted its holdings in Viewray by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,673,074 shares of the company’s stock valued at $32,359,000 after purchasing an additional 75,466 shares during the period. Finally, Bamco Inc. NY boosted its holdings in Viewray by 18.3% in the 2nd quarter. Bamco Inc. NY now owns 1,875,809 shares of the company’s stock valued at $16,526,000 after purchasing an additional 290,000 shares during the period.
A number of analysts have weighed in on VRAY shares. Morgan Stanley set a $5.00 price target on shares of Viewray and gave the company a “hold” rating in a report on Monday, August 12th. BidaskClub downgraded shares of Viewray from a “sell” rating to a “strong sell” rating in a report on Friday, September 13th. Mizuho set a $9.00 price target on shares of Viewray and gave the company a “buy” rating in a report on Monday, September 30th. Cantor Fitzgerald set a $6.00 price target on shares of Viewray and gave the company a “buy” rating in a report on Friday, September 13th. Finally, Jefferies Financial Group reduced their price target on shares of Viewray from $14.00 to $7.00 and set a “buy” rating for the company in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $9.55.
NASDAQ:VRAY opened at $2.45 on Friday. The company has a 50-day moving average of $3.43 and a 200-day moving average of $6.80. The company has a market capitalization of $226.51 million, a price-to-earnings ratio of -2.50 and a beta of 1.02. Viewray Inc has a 52 week low of $2.12 and a 52 week high of $10.02. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.01 and a current ratio of 4.01.
Viewray (NASDAQ:VRAY) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). The business had revenue of $30.17 million for the quarter, compared to the consensus estimate of $25.92 million. Viewray had a negative return on equity of 67.02% and a negative net margin of 128.13%. Viewray’s revenue was up 83.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) earnings per share. Sell-side analysts forecast that Viewray Inc will post -1.18 EPS for the current year.
In related news, insider James F. Dempsey sold 279,414 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $3.57, for a total transaction of $997,507.98. Following the completion of the sale, the insider now owns 272,433 shares in the company, valued at approximately $972,585.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James F. Dempsey sold 21,615 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $8.97, for a total transaction of $193,886.55. The disclosure for this sale can be found here. 15.48% of the stock is currently owned by company insiders.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Further Reading: How to Invest in Marijuana Stocks
Want to see what other hedge funds are holding VRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viewray Inc (NASDAQ:VRAY).
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.